DOW JONES21,636.78-915.39 -4.06%
S&P 5002,541.47-88.60 -3.37%
NASDAQ7,502.38-295.16 -3.79%

Fate Therapeutics Q4 EPS $(0.37) Beats $(0.39) Estimate, Sales $2.802M Beat $1.8M Estimate

Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.39) by 5.13 percent. This is a 48 percent decrease over losses of $(0.25) per share from the

Benzinga · 03/02/2020 21:02

Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.39) by 5.13 percent. This is a 48 percent decrease over losses of $(0.25) per share from the same period last year. The company reported quarterly sales of $2.802 million which beat the analyst consensus estimate of $1.8 million by 55.67 percent. This is a 68.69 percent increase over sales of $1.661 million the same period last year.